Abstract
Antiphospholipid antibodies (aPL) are a heterogeneous group of autoantibodies, detected in the sera of patients with both autoimmune and various non-autoimmune diseases. They are also detected in subjects with no overt underlying disease - the primary antiphosphilipid syndrome (PAPS). High titers of APL are associated with arterial and venous thrombosis, recurrent fetal loss and thrombocytopenia. There have been many suggestions explaining the potential mechanisms of the procoagulant effect of aPL. These include endothelial cell (EC) activation; increased adhesion molecule expression; inhibition of EC prostacyclin release, increased leucocyte adhesion to EC, downregulation of thrombomodulin expression. APL induce the procoagulant activity of monocytes via increased tissue factor expression and directly stimulate platelet hyperactivity with resultant production of enhanced amounts of the proaggregatory molecule of TXA2. In vitro studies show that prepro-endothelin-1 mRNA is induced by human monoclonal anticardiolipin antibodies and this might contribute to vasospasm, and, ultimately, to arterial occlusion. The hypercoagulable state in APS patients is associated with alterations in the protein C/S pathway. It is suggested that aPL may impair the protein C anticoagulant system. Acquired protein C and protein S deficiency is described in patients with APS. Beta2- glycoprotein I, (Beta2-GPI) a natural anticoagulant, is involved in the regulation of protein S anticoagulant activity by preventing the binding of protein S to C4b-binding protein. APL were shown to inhibit this effect of Beta2- GP I. As the group of aPL is very heterogeneous, it is unlikely that a single mechanism is responsible for the thrombogenic activity of all aPLs associated with thrombosis.
Keywords: Antiphospholipid antibodies, Thrombosis, Procoagulant mechanisms
Current Medicinal Chemistry
Title: Some Recent Insights into the Prothrombogenic Mechanisms of Antiphospholipid Antibodies
Volume: 14 Issue: 7
Author(s): Maria Todorova and Marta Baleva
Affiliation:
Keywords: Antiphospholipid antibodies, Thrombosis, Procoagulant mechanisms
Abstract: Antiphospholipid antibodies (aPL) are a heterogeneous group of autoantibodies, detected in the sera of patients with both autoimmune and various non-autoimmune diseases. They are also detected in subjects with no overt underlying disease - the primary antiphosphilipid syndrome (PAPS). High titers of APL are associated with arterial and venous thrombosis, recurrent fetal loss and thrombocytopenia. There have been many suggestions explaining the potential mechanisms of the procoagulant effect of aPL. These include endothelial cell (EC) activation; increased adhesion molecule expression; inhibition of EC prostacyclin release, increased leucocyte adhesion to EC, downregulation of thrombomodulin expression. APL induce the procoagulant activity of monocytes via increased tissue factor expression and directly stimulate platelet hyperactivity with resultant production of enhanced amounts of the proaggregatory molecule of TXA2. In vitro studies show that prepro-endothelin-1 mRNA is induced by human monoclonal anticardiolipin antibodies and this might contribute to vasospasm, and, ultimately, to arterial occlusion. The hypercoagulable state in APS patients is associated with alterations in the protein C/S pathway. It is suggested that aPL may impair the protein C anticoagulant system. Acquired protein C and protein S deficiency is described in patients with APS. Beta2- glycoprotein I, (Beta2-GPI) a natural anticoagulant, is involved in the regulation of protein S anticoagulant activity by preventing the binding of protein S to C4b-binding protein. APL were shown to inhibit this effect of Beta2- GP I. As the group of aPL is very heterogeneous, it is unlikely that a single mechanism is responsible for the thrombogenic activity of all aPLs associated with thrombosis.
Export Options
About this article
Cite this article as:
Todorova Maria and Baleva Marta, Some Recent Insights into the Prothrombogenic Mechanisms of Antiphospholipid Antibodies, Current Medicinal Chemistry 2007; 14 (7) . https://dx.doi.org/10.2174/092986707780090945
DOI https://dx.doi.org/10.2174/092986707780090945 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Human Parvovirus B19: An Infectious Agent with the Potential to Induce and Trigger Rheumatic Disease
Current Rheumatology Reviews Clinical Applications of Autoimmunity to Citrullinated Proteins in Rheumatoid Arthritis, from Improving Diagnostics to Future Therapies
Recent Patents on Inflammation & Allergy Drug Discovery Immune Cell Entry to Central Nervous System - Current Understanding and Prospective Therapeutic Targets
Endocrine, Metabolic & Immune Disorders - Drug Targets Imatinib Mesylate: An Innovation in Treatment of Autoimmune Diseases
Recent Patents on Inflammation & Allergy Drug Discovery Dietary N-3 Fatty Acids and Calorie Restriction in Autoimmune Disease:Influence in Different Immune Compartments
Current Organic Chemistry The Contrasting Roles of NKT Cells in Tumor Immunity
Current Molecular Medicine Comparative Molecular Characterization to Reveal Surface Behaviour of Non-proteolytic Bromelain Mutants
Current Pharmaceutical Biotechnology Synthetic Peptides in the Diagnosis of Systemic Autoimmune Diseases
Current Protein & Peptide Science CD26 / Dipeptidyl Peptidase IV: A Regulator of Immune Function and a Potential Molecular Target for Therapy
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Danger-Detector NKG2D: Immunosurveillance of Induced Self and Modulation by Cytokines and Soluble Ligands
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents The Critical Role of Toll-Like Receptor Signaling Pathways in the Induction and Progression of Autoimmune Diseases
Current Molecular Medicine Natural Cures for Type 1 Diabetes: A Review of Phytochemicals, Biological Actions, and Clinical Potential
Current Medicinal Chemistry Negative Regulation of TCR Signaling in Immunological Tolerance: Taming Good and Evil
Current Immunology Reviews (Discontinued) Synthetic Glycolipid Ligands for Human iNKT Cells as Potential Therapeutic Agents for Immunotherapy
Current Medicinal Chemistry Cannabinoids, Immune System and Cytokine Network
Current Pharmaceutical Design Failure of Immune Homeostasis - The Consequences of Under and Over Reactivity
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Gluten-dependent Intestinal Autoimmune Response
Current Pharmaceutical Design The Role of Tec Family Kinases in Inflammatory Processes
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Diagnosis of Inflammatory Bowel Disease by Abdominal Ultrasound and Color Doppler Techniques
Current Medical Imaging NKT Cells: A Regulator in Both Innate and Acquired Immunity
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents